Quoin Pharmaceuticals Announces Positive Clinical Update for QRX003
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Quoin Pharmaceuticals announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluating its drug candidate, QRX003. Four of the six enrolled patients, all under 10 years of age, were classified as "Improved" or "Significantly Improved" from their baseline assessments across key clinical endpoints. No treatment-related adverse events have been reported. Quoin plans to enroll additional pediatric patients in June and September and expects to release comprehensive clinical data from this program and its ongoing Phase 2 studies in the coming months. "With a remarkable 4 out of 6 children in the program responding positively and showing clear signs of improvement across key clinical endpoints when treated with QRX003, we are encouraged and remain optimistic about the potential for the product to become the first approved treatment for this disease," said Dr. Michael Myers, CEO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.620
Low
70.00
Averages
70.00
High
70.00
Current: 4.620
Low
70.00
Averages
70.00
High
70.00
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quoin Establishes Subsidiary in Japan to Advance QRX003 Commercialization
- Subsidiary Establishment: Quoin has established a wholly-owned subsidiary in Japan to directly commercialize QRX003 for treating Netherton Syndrome, marking a strategic advancement in one of its three core markets.
- Orphan Drug Designation: QRX003 recently received Orphan Drug Designation from Japan's MHLW, providing crucial policy support for its commercialization in Japan and enhancing market access potential.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially becoming the first approved treatment for this condition if successful.
- Global Market Strategy: In addition to Japan, Quoin has established nine commercial partnerships across 61 countries, which, combined with its core market strategy, could facilitate almost global availability of QRX003 if approved, further solidifying the company's market position.
See More
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
- Orphan Drug Designation: Quoin Pharmaceuticals announced that its drug QRX003 for treating Netherton Syndrome has received orphan drug designation from Japan's MHLW, providing up to 10 years of market exclusivity, significantly enhancing its competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing a phase 2 whole-body trial for Netherton syndrome patients, with a phase 3 study expected to begin in the second half of 2026 and an NDA filing anticipated in 2027, marking a crucial milestone in the drug development process.
- International Regulatory Recognition: In addition to Japan's orphan drug designation, QRX003 has also received pediatric rare disease designation and fast track designation from the U.S. FDA, as well as orphan drug designation from the EMA, indicating broad recognition and potential market opportunities globally.
- Strategic Market Positioning: Quoin CEO Michael Myers stated that Japan is a strategically important market for QRX003, and the company plans to self-commercialize the drug and other pipeline products upon approval, further strengthening its position in the global biopharmaceutical market.
See More
Japan Grants Orphan Drug Designation to QRX003
- Orphan Drug Designation: Japan's Ministry of Health grants Orphan Drug Designation to QRX003, allowing for up to 10 years of market exclusivity upon approval, significantly enhancing Quoin's competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially leading to an NDA filing in 2027 if successful.
- Strategic Market Importance: Japan is identified as a strategic market for QRX003, with Quoin planning to self-commercialize the drug and other pipeline products post-approval, which will aid in expanding the company's market share globally.
- Global Regulatory Recognition: QRX003 has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and the European Medicines Agency, further solidifying its potential as an effective treatment for Netherton Syndrome and addressing urgent medical needs for patients.
See More
Quoin Submits First IND Application for Peeling Skin Syndrome
- First IND Submission: Quoin Pharmaceuticals has submitted the first Investigational New Drug (IND) application to the FDA for QRX003 targeting Peeling Skin Syndrome, marking a significant milestone in the treatment of this rare disease and reinforcing the company's leadership in the rare disease sector.
- Clinical Data Support: The IND submission is backed by positive initial clinical data from an ongoing investigator-led pediatric study, demonstrating significant improvements in skin condition and overall quality of life for patients treated with QRX003 for over 15 months, indicating its good tolerability.
- Future Research Plans: Quoin plans to initiate a Phase 2 clinical study in the second half of 2026, aiming to recruit 6-8 pediatric and adult patients in both the US and Europe, which will further validate the efficacy and safety of QRX003.
- Strategic Development Outlook: This IND submission not only paves the way for QRX003's clinical development in Peeling Skin Syndrome but also showcases Quoin's robust pipeline potential in rare dermatologic conditions, expected to drive future growth and market share.
See More
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Quoin Pharmaceuticals reported a Q1 GAAP EPS of -$1.77, beating expectations by $0.25, indicating improvements in cost control and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Quoin had approximately $14 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, ensuring continuity in R&D and marketing efforts.
- Optimistic Operational Outlook: The management expressed optimism regarding the current cash position, believing it will sustain operations and continue product development, reflecting confidence in future market opportunities that may attract more investor interest.
- Positive Market Reaction: Following the earnings release, Quoin Pharmaceuticals' stock price is likely to experience a positive impact, as investor expectations for its future growth potential increase, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for the rare skin disease Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, addressing the lack of approved therapies and potentially enhancing the company's market position in dermatology.
- IND Application Plans: The firm expects to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, along with an additional indication, demonstrating proactive progress in clinical development that may pave the way for future market access.
- Multiple Indication Research: In addition to Pachyonychia Congenita, Quoin plans to initiate clinical studies for Gorlin Syndrome and Tuberous Sclerosis Complex later in 2026, further enriching its product pipeline and strengthening its competitive edge in the rare disease sector.
- Market Performance Analysis: QNRX shares have traded between $5.20 and $41.80 over the past year, closing at $5.45 with a slight decline of 0.18% on the last trading day, yet showing a 9.16% increase in after-hours trading to $5.95, indicating positive market sentiment towards its clinical advancements.
See More
Quoin Establishes Subsidiary in Japan to Advance QRX003 Commercialization
- Subsidiary Establishment: Quoin has established a wholly-owned subsidiary in Japan to directly commercialize QRX003 for treating Netherton Syndrome, marking a strategic advancement in one of its three core markets.
- Orphan Drug Designation: QRX003 recently received Orphan Drug Designation from Japan's MHLW, providing crucial policy support for its commercialization in Japan and enhancing market access potential.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially becoming the first approved treatment for this condition if successful.
- Global Market Strategy: In addition to Japan, Quoin has established nine commercial partnerships across 61 countries, which, combined with its core market strategy, could facilitate almost global availability of QRX003 if approved, further solidifying the company's market position.
See More
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
- Orphan Drug Designation: Quoin Pharmaceuticals announced that its drug QRX003 for treating Netherton Syndrome has received orphan drug designation from Japan's MHLW, providing up to 10 years of market exclusivity, significantly enhancing its competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing a phase 2 whole-body trial for Netherton syndrome patients, with a phase 3 study expected to begin in the second half of 2026 and an NDA filing anticipated in 2027, marking a crucial milestone in the drug development process.
- International Regulatory Recognition: In addition to Japan's orphan drug designation, QRX003 has also received pediatric rare disease designation and fast track designation from the U.S. FDA, as well as orphan drug designation from the EMA, indicating broad recognition and potential market opportunities globally.
- Strategic Market Positioning: Quoin CEO Michael Myers stated that Japan is a strategically important market for QRX003, and the company plans to self-commercialize the drug and other pipeline products upon approval, further strengthening its position in the global biopharmaceutical market.
See More
Japan Grants Orphan Drug Designation to QRX003
- Orphan Drug Designation: Japan's Ministry of Health grants Orphan Drug Designation to QRX003, allowing for up to 10 years of market exclusivity upon approval, significantly enhancing Quoin's competitive position in the Japanese market.
- Clinical Trial Progress: QRX003 is currently undergoing Phase 2 whole-body clinical trials for Netherton Syndrome, with a pivotal Phase 3 study expected to initiate in the second half of 2026, potentially leading to an NDA filing in 2027 if successful.
- Strategic Market Importance: Japan is identified as a strategic market for QRX003, with Quoin planning to self-commercialize the drug and other pipeline products post-approval, which will aid in expanding the company's market share globally.
- Global Regulatory Recognition: QRX003 has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA and the European Medicines Agency, further solidifying its potential as an effective treatment for Netherton Syndrome and addressing urgent medical needs for patients.
See More
Quoin Submits First IND Application for Peeling Skin Syndrome
- First IND Submission: Quoin Pharmaceuticals has submitted the first Investigational New Drug (IND) application to the FDA for QRX003 targeting Peeling Skin Syndrome, marking a significant milestone in the treatment of this rare disease and reinforcing the company's leadership in the rare disease sector.
- Clinical Data Support: The IND submission is backed by positive initial clinical data from an ongoing investigator-led pediatric study, demonstrating significant improvements in skin condition and overall quality of life for patients treated with QRX003 for over 15 months, indicating its good tolerability.
- Future Research Plans: Quoin plans to initiate a Phase 2 clinical study in the second half of 2026, aiming to recruit 6-8 pediatric and adult patients in both the US and Europe, which will further validate the efficacy and safety of QRX003.
- Strategic Development Outlook: This IND submission not only paves the way for QRX003's clinical development in Peeling Skin Syndrome but also showcases Quoin's robust pipeline potential in rare dermatologic conditions, expected to drive future growth and market share.
See More
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Quoin Pharmaceuticals reported a Q1 GAAP EPS of -$1.77, beating expectations by $0.25, indicating improvements in cost control and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Quoin had approximately $14 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, ensuring continuity in R&D and marketing efforts.
- Optimistic Operational Outlook: The management expressed optimism regarding the current cash position, believing it will sustain operations and continue product development, reflecting confidence in future market opportunities that may attract more investor interest.
- Positive Market Reaction: Following the earnings release, Quoin Pharmaceuticals' stock price is likely to experience a positive impact, as investor expectations for its future growth potential increase, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for the rare skin disease Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, addressing the lack of approved therapies and potentially enhancing the company's market position in dermatology.
- IND Application Plans: The firm expects to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, along with an additional indication, demonstrating proactive progress in clinical development that may pave the way for future market access.
- Multiple Indication Research: In addition to Pachyonychia Congenita, Quoin plans to initiate clinical studies for Gorlin Syndrome and Tuberous Sclerosis Complex later in 2026, further enriching its product pipeline and strengthening its competitive edge in the rare disease sector.
- Market Performance Analysis: QNRX shares have traded between $5.20 and $41.80 over the past year, closing at $5.45 with a slight decline of 0.18% on the last trading day, yet showing a 9.16% increase in after-hours trading to $5.95, indicating positive market sentiment towards its clinical advancements.
See More
